Last updated on November 2019

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis


Brief description of study

This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are

  • to prove the concept of clinical activity of BI 655130 in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II)
  • to confirm efficacy and safety of BI 655130 in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III)
  • To provide, along with induction study 1368-0018 and the run-in cohort of 1368-0020, the target population to be evaluated in study 1368-0020.

Clinical Study Identifier: NCT03482635

Find a site near you

Start Over

Sameshima Hospital

Kagoshima, Kagoshima, Japan
0.81miles
  Connect »